| Success story

Biosynex opens branch office in the Basel Area to meet Switzerland’s demand.

Location

Delémont

Industry

Healthcare (Diagnostics)

Employees

200+

Country of origin

France

Biosynex works on proactive medicine focused on prevention, screening, emergency diagnosis, and rapid treatment to give you the results you need when it matters most.

A key player in the COVID-19 pandemic.

Biosynex occupies over 230 employees and is a major player in public health. It designs, manufactures, and distributes easy-to-use medical devices for screening, diagnosis, and prevention. In recent years, it has launched numerous products for women, like fertility and pregnancy tests.

During the COVID-19 pandemic, Biosynex plays a significant role in providing rapid and PCR tests in more than 70 countries. It has won the Entrepreneur 2021 Award, the Export Excellence Award, and Deloitte’s 50 Best Companies in France Award.

The future of Biosynex in the Basel Area.

Biosynex aims at excellence in 3 areas of diagnostics: bioengineering, rapid testing, and molecular biology.

To respond to increasing demand from Switzerland and expand its business to Austria, Germany, and other countries, Biosynex has set up a branch office in Delémont. From here, it plans to achieve its new, significantly increased growth targets.

The Basel Area is the perfect location because it offers the right infrastructure with offices and a warehouse under the same roof and is close to the Biosynex headquarters in Illkirch-Graffenstaden.

The favorable environment for companies in the life sciences sector played an important role in Biosynex’s choice, too.

To make the move, Biosynex has teamed up with us.

We helped Biosynex find footing in the Basel Area and integrate into the local ecosystem to kickstart its activities.

We want to make our Swiss subsidiary one of the mainstays of our company and continue with this company to penetrate the Austrian, Germany and other countries in the world.

Dr. Thomas LamyGeneral manager

Do you have a question? We'd like to hear from you.